Paper36969501
Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia.
Li HJ and 4 others. Ther Adv Chronic Dis, 2023. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia. Papers, record 36969501. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36969501
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27933196 | Independent association of glucocorticoids with damage accrual in SLE. | Lupus Sci Med | 2016 | https://conductscience.org/library/papers/27933196 | PubMed |
| 2 | 11824975 | Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. | J Rheumatol | 2002 | https://conductscience.org/library/papers/11824975 | PubMed |
| 3 | 26554745 | Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period. | Arthritis Care Res (Hoboken) | 2016 | https://conductscience.org/library/papers/26554745 | PubMed |
| 4 | 24254965 | Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. | Am J Hematol | 2014 | https://conductscience.org/library/papers/24254965 | PubMed |
| 5 | 33709836 | Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study. | Lupus | 2021 | https://conductscience.org/library/papers/33709836 | PubMed |
| 6 | 31852672 | Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. | Ann Rheum Dis | 2020 | https://conductscience.org/library/papers/31852672 | PubMed |
| 7 | 34556256 | KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. | Kidney Int | 2021 | https://conductscience.org/library/papers/34556256 | PubMed |
| 8 | 34819388 | 2021 DORIS definition of remission in SLE: final recommendations from an international task force. | Lupus Sci Med | 2021 | https://conductscience.org/library/papers/34819388 | PubMed |
| 9 | 31945156 | Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. | Blood Adv | 2020 | https://conductscience.org/library/papers/31945156 | PubMed |
| 10 | 29755993 | The Role of Hydroxychloroquine as a Steroid-sparing Agent in the Treatment of Immune Thrombocytopenia: A Review of the Literature. | J Res Pharm Pract | 2018 | https://conductscience.org/library/papers/29755993 | PubMed |
| 11 | 28013208 | It hasn't gone away: the problem of glucocorticoid use in lupus remains. | Rheumatology (Oxford) | 2017 | https://conductscience.org/library/papers/28013208 | PubMed |
| 12 | 26871854 | Thrombocytopenia in Systemic Lupus Erythematosus: Clinical Manifestations, Treatment, and Prognosis in 230 Patients. | Medicine (Baltimore) | 2016 | https://conductscience.org/library/papers/26871854 | PubMed |
| 13 | 34996857 | Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis. | Lupus Sci Med | 2022 | https://conductscience.org/library/papers/34996857 | PubMed |
| 14 | 16567353 | Thrombocytopaenia in lupus as a marker of adverse outcome--seeking Ariadne's thread. | Rheumatology (Oxford) | 2006 | https://conductscience.org/library/papers/16567353 | PubMed |
| 15 | 30926722 | 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. | Ann Rheum Dis | 2019 | https://conductscience.org/library/papers/30926722 | PubMed |
| 16 | 35412598 | Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal. | Rheumatology (Oxford) | 2022 | https://conductscience.org/library/papers/35412598 | PubMed |
| 17 | 29251660 | Epidemiology of systemic lupus erythematosus: an update. | Curr Opin Rheumatol | 2018 | https://conductscience.org/library/papers/29251660 | PubMed |
| 18 | 27558987 | Remission in systemic lupus erythematosus: durable remission is rare. | Ann Rheum Dis | 2017 | https://conductscience.org/library/papers/27558987 | PubMed |
| 19 | 22553077 | Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. | Arthritis Rheum | 2012 | https://conductscience.org/library/papers/22553077 | PubMed |
| 20 | 29856800 | Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice. | PLoS One | 2018 | https://conductscience.org/library/papers/29856800 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42956009 | Low-level proteinuria at the initial diagnosis of systemic lupus erythematosus significantly increases the risk of developing proteinuria-predominant lupus nephritis. | PLoS One | 2026 | https://conductscience.org/library/papers/42956009 | PubMed |
| 41782905 | Efficacy and safety of immunosuppressive therapy in connective tissue disease-related immune thrombocytopenia: a systematic review and meta-analysis. | Ther Adv Hematol | 2026 | https://conductscience.org/library/papers/41782905 | PubMed |
| 40799655 | The predictive value of NLR, SII, and complement 3 in treatment response for systemic lupus erythematosus with immune thrombocytopenia. | Front Immunol | 2025 | https://conductscience.org/library/papers/40799655 | PubMed |
| 39627479 | Immune thrombocytopenia in patients with systemic lupus erythematosus. | Clin Rheumatol | 2025 | https://conductscience.org/library/papers/39627479 | PubMed |
| 38916764 | Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse. | Clin Rheumatol | 2024 | https://conductscience.org/library/papers/38916764 | PubMed |
| 38711668 | Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus. | Heliyon | 2024 | https://conductscience.org/library/papers/38711668 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ANXA13 | 312 | PubTator's text mining | https://conductscience.org/library/genes/312 | NCBI Gene |
| IL11 | 3589 | PubTator's text mining | https://conductscience.org/library/genes/3589 | NCBI Gene |
| THPO | 7066 | PubTator's text mining | https://conductscience.org/library/genes/7066 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36969501
GET https://conductscience.org/api/papers/v1/36969501/references?page=2